Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Directed evolution of bacterial toxins to target oncogenic Ras GTPase variants

FY 2021-22

Summary
Broadly speaking, cancers are diseases stemming from mutations which cause abnormal cell growth, movement and behaviour. About a quarter of human cancers are driven by mutations in genes encoding Ras GTPase (Ras) proteins, leading to elevated activity and loss of control over processes that they normally regulate. Historically, Ras mutants have been near-impossible to treat because of their structure and efficiency in hyperactive states, but recent advances across diverse research fields have coalesced to reveal intriguing springboards for future therapies. Several bacterial toxins can permanently shut down Ras activity in human cells, and the past few years have seen the introduction of powerful tools and techniques that allow us to change the functions of proteins and toxins through artificial evolution. This project involves the use of a pipeline to completely redirect toxin activity from normal Ras to any mutated Ras of interest. The goal is to advance our understanding of such toxin-target interactions, and to exploit novel protein engineering strategies to generate toxins which specifically target disease-associated Ras mutants.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466962
Name
Mei Ruoyu
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Directed evolution of bacterial toxins to target oncogenic Ras GTPase variants
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Ras Therapeutics; Directed Evolution; High-Throughput Platforms; Ras Oncoproteins; Toxin Evolution; Toxin Specificity
Abstract
Broadly speaking, cancers are diseases stemming from mutations which cause abnormal cell growth, movement and behaviour. About a quarter of human cancers are driven by mutations in genes encoding Ras GTPase (Ras) proteins, leading to elevated activity and loss of control over processes that they normally regulate. Historically, Ras mutants have been near-impossible to treat because of their structure and efficiency in hyperactive states, but recent advances across diverse research fields have coalesced to reveal intriguing springboards for future therapies. Several bacterial toxins can permanently shut down Ras activity in human cells, and the past few years have seen the introduction of powerful tools and techniques that allow us to change the functions of proteins and toxins through artificial evolution. This project involves the use of a pipeline to completely redirect toxin activity from normal Ras to any mutated Ras of interest. The goal is to advance our understanding of such toxin-target interactions, and to exploit novel protein engineering strategies to generate toxins which specifically target disease-associated Ras mutants.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mei, Ruoyu
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~